Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematological malignancies, yet achieving comparable efficacy against solid tumors remains a severe clinical challenge. A primary obstacle is the immunosuppressive tumor microenvironment, which is characterized by high expression of inhibitory immune checkpoints like TIM-3 that aggressively induce T-cell exhaustion and promote tumor evasion. While combining CAR-T cells with systemic checkpoint blockade antibodies is heavily investigated, it often leads to short-lived efficacy and severe immune-related adverse events. 

Researchers have developed a new way to program human cells to make decisions much like tiny computers. They created a new system that allows cells to process several cellular indications at the same time while using fewer computations than previous methods. This means cells could one day be programmed to recognize specific signs of disease and respond only when needed. For example, they could detect cancer-related signals and release treatments directly where they are needed, reducing harm to healthy tissue. The breakthrough brings scientists closer to creating smart, programmable cell therapies that can automatically diagnose and treat disease inside the body.

Researchers from the University of Osaka have demonstrated that mitochondrial hyperfusion, when induced by low levels of DRP1 or cellular stress, activates an immune response through the RIG-I–MAVS pathway. Dependent on the involvement of the BAX protein, the release of mitochondrial RNA into the cytosol enhanced natural killer cell cytotoxicity and reduced tumor growth in a xenograft model. The findings provide new possibilities for cancer research and treatment.

hijacks the gene regulatory blueprint of normal vascular differentiation to drive tumor angiogenesis —without evolving an entirely new mechanism.

single-cell multi-omics and a 3D gene regulatory map built from an hESC-based vascular differentiation system, the team pinpointed the late progenitor stage as the developmental origin of tumor endothelial cell identity.

receptor (ITGAV) was identified as a key mediator and validated as a therapeutic target: its inhibition suppressed tumor vascularization and growth in a colorectal cancer model.

New research suggests that although low hand grip strength is a valuable indicator of overall health and frailty, it is not a reliable standalone predictor of increased prostate cancer risk among older men.

A rare case of basal cell carcinoma (BCC) on the right middle finger in a 63-year-old man underscores that this common skin cancer can occur in unusual digital locations. The report emphasizes that biopsy remains the gold standard for diagnosis, and clinicians should include BCC in the differential diagnosis of atypical finger lesions to ensure timely treatment.